L. Gregori, J. Hainfeld, M. Simon, D. Goldgaber (1997)
Binding of Amyloid β Protein to the 20 S Proteasome*The Journal of Biological Chemistry, 272
A. Goldberg (2003)
Protein degradation and protection against misfolded or damaged proteinsNature, 426
Thomas Lanz, C. Himes, G. Pallante, L. Adams, S. Yamazaki, B. Amore, K. Merchant (2003)
The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 MiceJournal of Pharmacology and Experimental Therapeutics, 305
E. Check (2002)
Nerve inflammation halts trial for Alzheimer's drugNature, 415
Tseng (2004)
Amyloid [beta]-peptideCurr. Alzheimer's Res., in press
J. Dodart, K. Bales, K. Gannon, S. Greene, R. DeMattos, C. Mathis, C. Delong, Su Wu, Xin Wu, D. Holtzman, S. Paul (2002)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease modelNature Neuroscience, 5
Rissman (2004)
Caspase-cleavage of tau is an early event in neurofibrillary pathology in Alzheimer's diseaseJ. Clin. Invest., 114
R. Rissman, W. Poon, M. Blurton-Jones, S. Oddo, R. Torp, M. Vitek, F. LaFerla, T. Rohn, C. Cotman (2004)
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology.The Journal of clinical investigation, 114 1
Susi Keck, R. Nitsch, T. Grune, O. Ullrich (2003)
Proteasome inhibition by paired helical filament‐tau in brains of patients with Alzheimer's diseaseJournal of Neurochemistry, 85
S. Oddo, A. Caccamo, J. Shepherd, M. Murphy, T. Golde, R. Kayed, R. Metherate, M. Mattson, Y. Akbari, F. LaFerla (2003)
Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic DysfunctionNeuron, 39
K. Lindsten, V. Menéndez-Benito, M. Masucci, N. Dantuma (2003)
A transgenic mouse model of the ubiquitin/proteasome systemNature Biotechnology, 21
J. Götz, Feng Chen, J. Dorpe, R. Nitsch (2001)
Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 FibrilsScience, 293
D. Wilcock, G. Dicarlo, D. Henderson, J. Jackson, K. Clarke, K. Ugen, M. Gordon, D. Morgan (2003)
Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial ActivationThe Journal of Neuroscience, 23
E. Sigurdsson, H. Scholtzova, Pankaj Mehta, B. Frangione, T. Wisniewski (2001)
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.The American journal of pathology, 159 2
John Hardy, D. Selkoe (2002)
The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 297
L. Gregori, C. Fuchs, M. Figueiredo-Pereira, W. Nostrand, D. Goldgaber (1995)
Amyloid β-Protein Inhibits Ubiquitin-dependent Protein Degradation in Vitro(*)The Journal of Biological Chemistry, 270
Bertrand Tseng, M. Kitazawa, F. LaFerla (2004)
Amyloid beta-peptide: the inside story.Current Alzheimer research, 1 4
J. Keller, Keith Hanni, W. Markesbery (2000)
Impaired Proteasome Function in Alzheimer's DiseaseJournal of Neurochemistry, 75
M. Rapoport, H. Dawson, L. Binder, M. Vitek, Adriana Ferreira (2002)
Tau is essential to beta -amyloid-induced neurotoxicity.Proceedings of the National Academy of Sciences of the United States of America, 99 9
Jada Lewis, D. Dickson, Wen‐lang Lin, L. Chisholm, A. Corral, Graham Jones, S. Yen, N. Sahara, L. Skipper, D. Yager, C. Eckman, J. Hardy, M. Hutton, E. McGowan (2001)
Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APPScience, 293
(2000)
ProteasomeThe data were subsequently analyzed by ANOVA or t test compariinhibition by paired helical filamenttau in brains of patients withson , using Graphpad Prism software
M. Salon, L. Morelli, E. Castaño, E. Soto, J. Pasquini (2000)
Defective ubiquitination of cerebral proteins in Alzheimer's diseaseJournal of Neuroscience Research, 62
C. Hock, U. Konietzko, J. Streffer, Jay Tracy, Andri Signorell, Britta Müller-Tillmanns, U. Lemke, K. Henke, Eva Moritz, Esmeralda Garcia, M. Wollmer, D. Umbricht, D. Quervain, M. Hofmann, A. Maddalena, A. Papassotiropoulos, R. Nitsch (2003)
Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's DiseaseNeuron, 38
F. Bard, C. Cannon, R. Barbour, R. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, Jiping Huang, K. Johnson-wood, K. Khan, D. Kholodenko, Mike Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, Kim Weiss, Brent Welch, P. Seubert, D. Schenk, T. Yednock (2000)
Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer diseaseNature Medicine, 6
Bertrand Tseng, M. Kitazawa, F. LaFerla (2004)
Amyloid β-Peptide: The Inside StoryCurrent Alzheimer Research, 1
Della David, R. Layfield, L. Serpell, Y. Narain, M. Goedert, M. Spillantini (2002)
Proteasomal degradation of tau proteinJournal of Neurochemistry, 83
D. Morgan, D. Diamond, P. Gottschall, K. Ugen, C. Dickey, J. Hardy, K. Duff, P. Jantzen, G. Dicarlo, D. Wilcock, K. Connor, J. Hatcher, C. Hope, M. Gordon, G. Arendash (2000)
Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's diseaseNature, 408
M. Hutton, C. Lendon, P. Rizzu, M. Baker, S. Froelich, H. Houlden, S. Pickering-Brown, S. Chakraverty, A. Isaacs, A. Grover, J. Hackett, J. Adamson, S. Lincoln, D. Dickson, P. Davies, R. Petersen, M. Stevens, E. Graaff, E. Wauters, J. Baren, M. Hillebrand, M. Joosse, J. Kwon, P. Nowotny, Li Che, J. Norton, J. Morris, L. Reed, J. Trojanowski, H. Basun, L. Lannfelt, M. Neystat, S. Fahn, F. Dark, T. Tannenberg, P. Dodd, N. Hayward, J. Kwok, P. Schofield, A. Andreadis, J. Snowden, D. Craufurd, D. Neary, F. Owen, B. Oostra, J. Hardy, A. Goate, J. Swieten, D. Mann, T. Lynch, P. Heutink (1998)
Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17Nature, 393
J. Mendell, Z. Sahenk, T. Gales, L. Paul (1991)
Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments.Archives of neurology, 48 12
S. Oddo, A. Caccamo, M. Kitazawa, Bertrand Tseng, F. LaFerla (2003)
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer’s diseaseNeurobiology of Aging, 24
Olaf Goldbaum, M. Oppermann, M. Handschuh, Deepa Dabir, Bin Zhang, M. Forman, J. Trojanowski, V. Lee, C. Richter-Landsberg (2003)
Proteasome Inhibition Stabilizes Tau Inclusions in Oligodendroglial Cells that Occur after Treatment with Okadaic AcidThe Journal of Neuroscience, 23
H. Dovey, V. John, J. Anderson, L. Chen, P. Andrieu, L. Fang, S. Freedman, B. Folmer, E. Goldbach, E. Holsztynska, K. Hu, K. Johnson-wood, S. Kennedy, D. Kholodenko, J. Knops, L. Latimer, M. Lee, Z. Liao, I. Lieberburg, R. Motter, L. Mutter, J. Nietz, K. Quinn, K. Sacchi, P. Seubert, G. Shopp, E. Thorsett, J. Tung, J. Wu, S. Yang, C. Yin, D. Schenk, P. May, L. Altstiel, M. Bender, L. Boggs, T. Britton, J. Clemens, D. Czilli, D. Dieckman-McGinty, J. Droste, Kimberly Fuson, B. Gitter, P. Hyslop, E. Johnstone, W. Li, S. Little, T. Mabry, F. Miller, J. Audia (2000)
Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brainJournal of Neurochemistry, 76
M. Rapoport, H. Dawson, L. Binder, M. Vitek, Adriana Ferreira (2002)
Tau is essential to β-amyloid-induced neurotoxicityProceedings of the National Academy of Sciences of the United States of America, 99
C. Weaver, Marisol Espinoza, Y. Kress, P. Davies (2000)
Conformational change as one of the earliest alterations of tau in Alzheimer’s diseaseNeurobiology of Aging, 21
C. Janus, J. Pearson, J. McLaurin, P. Mathews, Ying Jiang, S. Schmidt, M. Chishti, P. Horne, D. Heslin, J. French, H. Mount, R. Nixon, M. Mercken, C. Bergeron, C. Bergeron, P. Fraser, P. George-Hyslop, P. George-Hyslop, D. Westaway (2000)
Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's diseaseNature, 408
D. Wilcock, Sanjay Munireddy, A. Rosenthal, K. Ugen, M. Gordon, D. Morgan (2004)
Microglial activation facilitates Aβ plaque removal following intracranial anti-Aβ antibody administrationNeurobiology of Disease, 15
D. Schenk, R. Barbour, W. Dunn, G. Gordon, H. Grajeda, T. Guido, K. Hu, Jiping Huang, K. Johnson-wood, K. Khan, D. Kholodenko, Mike Lee, Zhenmei Liao, I. Lieberburg, R. Motter, L. Mutter, F. Soriano, G. Shopp, N. Vasquez, C. Vandevert, S. Walker, M. Wogulis, T. Yednock, D. Games, P. Seubert (1999)
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouseNature, 400
D. Wilcock, G. Dicarlo, D. Henderson, J. Jackson, K. Clarke, K. Ugen, M. Gordon, D. Morgan (2003)
Intracranially administered anti-Abeta antibodies reduce beta-amyloid deposition by mechanisms both independent of and associated with microglial activation.The Journal of neuroscience : the official journal of the Society for Neuroscience, 23 9
D. Wilcock, Sanjay Munireddy, A. Rosenthal, K. Ugen, M. Gordon, D. Morgan (2004)
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.Neurobiology of disease, 15 1
H. Kowa, T. Iwatsubo (2004)
[Amyloid beta peptide].Nihon rinsho. Japanese journal of clinical medicine, 62 Suppl 11
J. Nicoll, D. Wilkinson, C. Holmes, P. Steart, H. Markham, R. Weller (2003)
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case reportNature Medicine, 9
and into nature of filaments
Neuron – Unpaywall
Published: Aug 1, 2004
Access the full text.
Sign up today, get DeepDyve free for 14 days.